tetano
Editor, Senior Moderator
World J Hepatol
. 2022 Jun 27;14(6):1099-1110.
doi: 10.4254/wjh.v14.i6.1099.
Liver dysfunction during COVID-19 pandemic: Contributing role of associated factors in disease progression and severity
Tarun Sahu[SUP] 1 [/SUP], Babita Pande[SUP] 1 [/SUP], Manasa Pl[SUP] 2 [/SUP], Henu Kumar Verma[SUP] 3 [/SUP]
Affiliations
Abstract
In December 2019, a new strain of coronavirus was discovered in China, and the World Health Organization declared it a pandemic in March 2020. The majority of people with coronavirus disease 19 (COVID-19) exhibit no or only mild symptoms such as fever, cough, anosmia, and headache. Meanwhile, approximately 15% develop a severe lung infection over the course of 10 d, resulting in respiratory failure, which can lead to multi-organ failure, coagulopathy, and death. Since the beginning of the pandemic, it appears that there has been consideration that pre-existing chronic liver disease may predispose to deprived consequences in conjunction with COVID-19. Furthermore, extensive liver damage has been linked to immune dysfunction and coagulopathy, which leads to a more severe COVID-19 outcome. Besides that, people with COVID-19 frequently have abnormal liver function, with more significant elevations in alanine aminotransferase and aspartate aminotransferase in patients with severe COVID-19 compared to those with mild/moderate disease. This review focuses on the pathogenesis of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in the liver, as well as the use of liver chemistry as a prognostic tool during COVID-19. We also evaluate the findings for viral infection of hepatocytes, and look into the potential mechanisms behind SARS-CoV-2-related liver damage.
Keywords: COVID-19; Hepatic injury; Liver function; SARS-CoV-2; Viral infection.
. 2022 Jun 27;14(6):1099-1110.
doi: 10.4254/wjh.v14.i6.1099.
Liver dysfunction during COVID-19 pandemic: Contributing role of associated factors in disease progression and severity
Tarun Sahu[SUP] 1 [/SUP], Babita Pande[SUP] 1 [/SUP], Manasa Pl[SUP] 2 [/SUP], Henu Kumar Verma[SUP] 3 [/SUP]
Affiliations
- PMID: 35978661
- PMCID: PMC9258249
- DOI: 10.4254/wjh.v14.i6.1099
Abstract
In December 2019, a new strain of coronavirus was discovered in China, and the World Health Organization declared it a pandemic in March 2020. The majority of people with coronavirus disease 19 (COVID-19) exhibit no or only mild symptoms such as fever, cough, anosmia, and headache. Meanwhile, approximately 15% develop a severe lung infection over the course of 10 d, resulting in respiratory failure, which can lead to multi-organ failure, coagulopathy, and death. Since the beginning of the pandemic, it appears that there has been consideration that pre-existing chronic liver disease may predispose to deprived consequences in conjunction with COVID-19. Furthermore, extensive liver damage has been linked to immune dysfunction and coagulopathy, which leads to a more severe COVID-19 outcome. Besides that, people with COVID-19 frequently have abnormal liver function, with more significant elevations in alanine aminotransferase and aspartate aminotransferase in patients with severe COVID-19 compared to those with mild/moderate disease. This review focuses on the pathogenesis of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in the liver, as well as the use of liver chemistry as a prognostic tool during COVID-19. We also evaluate the findings for viral infection of hepatocytes, and look into the potential mechanisms behind SARS-CoV-2-related liver damage.
Keywords: COVID-19; Hepatic injury; Liver function; SARS-CoV-2; Viral infection.